A Phase 1 study of FH-FOLR1 CAR T-cell therapy in pediatric relapsed/refractory AML
Recruiting Phase 1 NCT06609928
Study Description
Testing a new immunotherapy approach for treating children with acute myeloid leukemia that has relapsed or not responded to previous treatment
Study Details
- Registry ID:
- NCT06609928
- Conditions:
- Recurrent Childhood Acute Myeloid Leukemia, Refractory Childhood Acute Myeloid Leukemia
- Phase:
- Phase 1
- Target Enrollment:
- 12 participants
- Start Date:
- Age Range:
- 0–6 years
- Healthy Volunteers:
- No
Study Locations (1 site)
-
Fred Hutch/University of Washington/Seattle Children's Cancer Consortium
Seattle, Washington, United States
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.